The inhibition of the P38 MAPK pathway directly affects the expression levels of the key glycolytic enzymes PKM2 and GLUT1, thereby further hindering the glycolytic process and the proliferative capacity of GC cells. This evidence concerns the gene SLC2A1 and gastric cancer.